MA29686B1 - Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide - Google Patents

Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Info

Publication number
MA29686B1
MA29686B1 MA30563A MA30563A MA29686B1 MA 29686 B1 MA29686 B1 MA 29686B1 MA 30563 A MA30563 A MA 30563A MA 30563 A MA30563 A MA 30563A MA 29686 B1 MA29686 B1 MA 29686B1
Authority
MA
Morocco
Prior art keywords
methyl
ylamino
imidazol
pyrimidin
pyridin
Prior art date
Application number
MA30563A
Other languages
English (en)
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37398525&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29686(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29686B1 publication Critical patent/MA29686B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Sels de 4-méthyl-N-[3-(4-méthyl-imidazol-1-yl)-5-trifluorométhyl-phényl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide préparés à l'aide de divers procédés.
MA30563A 2005-07-20 2008-01-09 Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide MA29686B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140605P 2005-07-20 2005-07-20
US71621305P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
MA29686B1 true MA29686B1 (fr) 2008-08-01

Family

ID=37398525

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30563A MA29686B1 (fr) 2005-07-20 2008-01-09 Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Country Status (34)

Country Link
US (4) US8163904B2 (fr)
EP (2) EP2186808B1 (fr)
JP (1) JP5129132B2 (fr)
KR (3) KR101755137B1 (fr)
CN (1) CN102267981A (fr)
AR (1) AR057467A1 (fr)
AT (1) ATE514689T1 (fr)
AU (2) AU2006276205B2 (fr)
BR (1) BRPI0613605A2 (fr)
CA (2) CA2823946C (fr)
CY (1) CY1111772T1 (fr)
DK (1) DK1910336T3 (fr)
EC (1) ECSP088118A (fr)
ES (1) ES2634291T3 (fr)
GT (1) GT200600316A (fr)
HK (1) HK1116778A1 (fr)
HR (1) HRP20110639T1 (fr)
IL (1) IL187787A (fr)
JO (1) JO2757B1 (fr)
MA (1) MA29686B1 (fr)
MX (1) MX2008000892A (fr)
MY (1) MY149889A (fr)
NO (1) NO341313B1 (fr)
NZ (2) NZ591142A (fr)
PE (1) PE20070241A1 (fr)
PL (1) PL1910336T3 (fr)
PT (1) PT1910336E (fr)
RU (4) RU2509767C1 (fr)
SG (1) SG170772A1 (fr)
SI (1) SI1910336T1 (fr)
TN (1) TNSN08028A1 (fr)
TW (1) TWI455934B (fr)
UY (1) UY29683A1 (fr)
WO (1) WO2007015871A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
US20100152198A1 (en) * 2006-04-07 2010-06-17 Manley Paul W Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (fr) 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
EP2305667A3 (fr) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Produits intermédiaires du nilotinib et préparation de ceux-ci
JP5486012B2 (ja) 2008-11-05 2014-05-07 テバ ファーマシューティカル インダストリーズ リミティド ニロチニブＨＣｌ結晶形
EP2186514B1 (fr) * 2008-11-14 2016-06-29 Kinki University Traitement de tumeurs malignes de la gaine des nerfs périphériques
CA2753637A1 (fr) 2009-03-06 2010-09-10 Novartis Ag Utilisation de derives de pyrimidylaminobenzamide pour le traitement de troubles a mediation par une kinase contenant un leucine zipper et un motif alpha sterile (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (fr) 2009-09-17 2011-03-24 Generics [Uk] Limited Sel de dichlorhydrate de nilotinib
EP2490690A1 (fr) 2009-10-23 2012-08-29 Novartis AG Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (fr) 2010-01-15 2016-09-02
EP2558098A2 (fr) 2010-04-16 2013-02-20 Novartis AG Traitement d'un cancer du sein résistant à l'endocrine
EP2382976A1 (fr) 2010-04-30 2011-11-02 Hiroshima University Utilisation d'inhibiteurs pdgf-r pour le traitement de métastases dans les ganglions lymphatiques du cancer gastrique
KR20130042498A (ko) * 2010-06-21 2013-04-26 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 염 및 이의 결정형
WO2012014127A1 (fr) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Inhibiteurs de 5-lipoxygénase
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
EP2648519A4 (fr) * 2010-11-26 2014-04-30 Hetero Research Foundation Nouveau polymorphe de chlorhydrate de nilotinib
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
KR20140096035A (ko) 2011-10-28 2014-08-04 노파르티스 아게 위장 기질 종양을 치료하는 방법
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
JP6275645B2 (ja) 2011-11-14 2018-02-07 ノバルティス アーゲー ４−メチル−３−［［４−（３−ピリジニル）−２−ピリミジニル］アミノ］−ｎ−［５−（４−メチル−１ｈ−イミダゾール−１−イル）−３−（トリフルオロメチル）フェニル］ベンズアミドの即放性製剤
EP2872142A1 (fr) 2012-07-11 2015-05-20 Novartis AG Méthode de traitement de tumeurs stromales gastro-intestinales
WO2014059518A1 (fr) * 2012-10-15 2014-04-24 Apotex Technologies Inc. Formes solides du chlorhydrate de nilotinib
MX2015004947A (es) * 2012-10-19 2016-02-22 Basf Se Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
JP2016522182A (ja) * 2013-04-24 2016-07-28 ドクター レディズ ラボラトリーズ リミテッド ニロチニブ塩酸塩の多形形態
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (fr) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Mono-oxalate de nilotinib et sa forme cristalline
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
LT3189045T (lt) * 2014-08-11 2022-04-11 Sun Pharmaceutical Industries Limited Naujos nilotinibo druskos ir jų polimorfai
US10301282B2 (en) 2015-03-20 2019-05-28 Cipla Limited Polymorphic form X of nilotinib dihydrochloride hydrate
WO2017129694A1 (fr) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Dinitrate de nilotinib (v) et formes cristallines de celui-ci
WO2017149550A1 (fr) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Forme amorphe du 4-méthyl-n-[3-(4-méthyl-1h-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
PL3430004T3 (pl) 2016-03-14 2021-01-25 Pliva Hrvatska D.O.O. Postaci soli nilotynibu w stanie stałym
EP3404025B1 (fr) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procede de preparation de nilotinib pur et de son sel
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
WO2020095187A1 (fr) * 2018-11-05 2020-05-14 Laurus Labs Limited Forme cristalline de chlorhydrate de nilotinib, son procédé de préparation et composition pharmaceutique le contenant
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US20230075170A1 (en) 2020-02-15 2023-03-09 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
EP4142699A1 (fr) 2020-04-30 2023-03-08 Nanocopoeia LLC Comprimé à désintégration orale comprenant une dispersion solide amorphe de nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
EP4260848A1 (fr) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Composition pharmaceutique pour forme posologique solide contenant du nilotinib et son procédé de préparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081108C1 (ru) * 1991-10-16 1997-06-10 Циба-Гейги АГ Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PL179417B1 (en) 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE60034963D1 (de) * 1999-12-14 2007-07-05 Nippon Shinyaku Co Ltd Heterocyclische derivate und arzneistoffe
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
ECSP088118A (es) 2008-02-20
HK1116778A1 (fr) 2009-01-02
RU2434864C2 (ru) 2011-11-27
RU2605551C2 (ru) 2016-12-20
NZ564182A (en) 2011-03-31
RU2013101749A (ru) 2014-07-27
TW200800950A (en) 2008-01-01
CA2615669A1 (fr) 2007-02-08
CY1111772T1 (el) 2015-10-07
ES2634291T3 (es) 2017-09-27
BRPI0613605A2 (pt) 2011-01-18
IL187787A0 (en) 2008-08-07
ATE514689T1 (de) 2011-07-15
RU2011120363A (ru) 2012-11-27
TNSN08028A1 (en) 2009-07-14
CA2615669C (fr) 2013-11-12
PL1910336T3 (pl) 2011-11-30
AU2006276205A1 (en) 2007-02-08
NO341313B1 (no) 2017-10-09
PT1910336E (pt) 2011-09-05
AU2010241419C1 (en) 2024-05-23
RU2483065C2 (ru) 2013-05-27
RU2008105827A (ru) 2009-08-27
KR20150100946A (ko) 2015-09-02
KR20140047737A (ko) 2014-04-22
RU2509767C1 (ru) 2014-03-20
EP2186808A1 (fr) 2010-05-19
MY149889A (en) 2013-10-31
HRP20110639T1 (hr) 2011-10-31
CA2823946C (fr) 2015-12-29
NO20080897L (no) 2008-02-20
DK1910336T3 (da) 2011-10-03
AU2010241419B2 (en) 2012-03-29
GT200600316A (es) 2007-04-02
US20080200487A1 (en) 2008-08-21
KR20080027855A (ko) 2008-03-28
JP5129132B2 (ja) 2013-01-23
US8163904B2 (en) 2012-04-24
US9163005B2 (en) 2015-10-20
AU2010241419A1 (en) 2010-12-02
EP1910336A1 (fr) 2008-04-16
SG170772A1 (en) 2011-05-30
US8389537B2 (en) 2013-03-05
US20130137712A1 (en) 2013-05-30
TWI455934B (zh) 2014-10-11
KR101755137B1 (ko) 2017-07-06
PE20070241A1 (es) 2007-03-22
IL187787A (en) 2012-07-31
MX2008000892A (es) 2008-03-18
NZ591142A (en) 2012-09-28
WO2007015871A1 (fr) 2007-02-08
AU2006276205B2 (en) 2010-08-19
US20140038994A1 (en) 2014-02-06
CA2823946A1 (fr) 2007-02-08
UY29683A1 (es) 2007-02-28
EP1910336B1 (fr) 2011-06-29
JO2757B1 (en) 2014-03-15
CN102267981A (zh) 2011-12-07
EP2186808B1 (fr) 2017-04-19
US20120270891A1 (en) 2012-10-25
US8580806B2 (en) 2013-11-12
SI1910336T1 (sl) 2011-10-28
AR057467A1 (es) 2007-12-05
JP2009502796A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
MA29686B1 (fr) Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
MA29626B1 (fr) Formes cristallines de 4-methyl-n-[3-(4-methyl -imidazol-1-yl)-5-trifluromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ZA200710457B (en) Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoro-methyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ITPD20050020U1 (it) Dispositivo per l'abbronzatura del corpo
CU20120123A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
ITAR20050016A1 (it) "smandrinatore portatile"
ITGE20050028A1 (it) Monopattino d'acqua.
ITPD20060247A1 (it) Dispositivo perfezionato per l'abbronzatura del corpo
ITTV20050007A1 (it) Tavolo con piano d'appoggio modificabile.
ITMI20051844A1 (it) Dispositivo perfezionato per l'avvolgimento di vele